Abstract:Quality assurance in laboratory medicine started in the Federal Republic of Germany in 1971 with the publication of the "Guidelines of the German Medical Association for the implementation of a statistical quality control and round robin tests in the field of medicine". Since then quality assurance in general has developed further and the "Guideline of the German Medical Association on Quality Assurance in Medical Laboratory Examinations" (abbreviated Rili-BAEK) has been refined in numerous revisions to date. In 2008, the foundation stone for the current structure of the Rili-BAEK was laid [1]: A: Basic requirements for quality assurance in medical laboratory examinations B: Special Parts B 1: Quantitative medical laboratory examinations B 2: Qualitative medical laboratory examinations B 3: Direct detection and characterisation of infectious agents B 4: Examinations of ejaculate B 5: Molecular genetic and cytogenetic medical laboratory examinations C: Advisory board D: Expert groups E: Reference institutions E 1: General requirements for reference institutions conducting external quality assurance programmes E 2: Special requirements for reference institutions F: Temporary regulations G: Entry into force The great importance of the Rili-BAEK is reflected in its explicit mention in Section 10 (1) of the Medical Devices Operator Ordinance (MPBetreibV) from 2024, which passed the resolution by the upper house of the German parliament on July 5th 2024 and states that [2]: "Anyone who carries out laboratory medical examinations must establish a quality assurance system in accordance with the state of the art in medical science and technology to maintain the necessary quality, safety and performance in the use of in vitro diagnostics and to ensure the reliability of the results obtained prior incepting this activity. Proper quality assurance in accordance with sentence 1 is assumed if the 'Guideline of the German Medical Association on Quality Assurance of Laboratory Medical Examinations' in the version of 30 May 2023 (Deutsches Ärzteblatt of 30 May 2023, DOI: 10.3238/arztebl.2023.rili_baek_Labor) is observed." When the Rili-BAEK was revised in 2019, Part A was modernised with regard to quality management. Contents of the general quality management standard of the Federal Joint Committee (G-BA) were incorporated (i.e. structure and process quality, continuous improvement, high level on patient safety, effort in reasonable proportion to the equipment) [3] and important elements from the DIN EN ISO 9001:2015 were adopted (i.e. documented information, documentation on the quality management instead of the quality management manual) [4]. The way was paved for using process-orientated quality management systems in the future and the concept of risk-based quality assurance was introduced. Furthermore, the peer review was anchored in the Rili-BAEK as an important element of medical quality assurance. The peer review contains a professional dialogue in multiprofessional cooperation on the same level not only involving doctors and scientists but also technicians. The German Medical Association provides a curriculum for this that can be employed for advanced training to become a peer. Reactions on the introduction of the peer reviews in laboratory medicine were positive throughout [5]. Within the revision of the Rili-BAEK 2019 the increased medical demands on measurement quality – on the example of HbA 1c – were incorporated [6]. Since HbA 1c according to the guidelines not only is a measurand for patient follow-up but can also be used for the diagnosis of diabetes mellitus medical demands on measurement quality have tightened. In this context the demands on the internal quality assurance decreased from ±10 % via ±5 % to ±3 % with a transition period of four years. This adaptation was necessary, because in the case of a deviation of measurement of ±4 % with a true HbA 1c value of 44 mol/mol Hb the results are both in the range of no risk for diabetes mellitus ( 47 mmol/mol Hb). Therefore, with the former demands on measurement quality it was impossible to guarantee a reliable diagnosis of diabetes mellitus. Later on in 2023 the American Association for Clinical Chemistry and the American Diabetes Association recommended in a joint publication an intralaboratory CV for HbA 1c of 1.5 % [7]. In the Rili-BAEK 2023 the demands on the external quality assurance (round robin tests) decreased from ±18 % to ±8 %. Furthermore, demands on the internal quality assurance for further 30 measurands were defined, quality criteria for the diagnostic in cerebrospinal fluid were revised and the specimen dried blood for Newborn Screening was added. In the Parts B 2 and B 3 the number of measurands with external quality assurance was increased by 10 and the risk-based qualit -Abstract Truncated-

Laborqualität sichern – molekular- und zytogenetische Ringversuche des BVDH e. V.

An External Quality Assessment Scheme for Prenatal Detection of Rare Chromosomal Abnormalities

Editorial to the revision of the "Guideline of the German Medical Association on quality assurance in medical laboratory examinations – Rili-BAEK"

Erratum: Qualitätsindikatoren zeigen bessere Erfüllungsquoten in DKGzertifizierten Zentren

Longitudinal analysis of 20 Years of external quality assurance schemes for PCR/NAAT-based bacterial genome detection in diagnostic testing

Implementation of human genetic counseling in the MZEB (Medical Center for Adults with disabilities) at the psychiatric LVR Clinic Bedburg-Hau

External quality assurance program for diagnostic complement laboratories: evaluation of the results of the past seven years

Analysis of immunogenetics interlaboratory comparisons' success rates. External quality assurance system of the Spanish Society for Immunology GECLID-SEI

Fifteen years of Belgian experience with external quality assessment of semen analysis

External proficiency testing for histocompatibility and immunogenetics in today and future

External quality assessment performance in ten countries: an IFCC global laboratory quality project

A Novel External Quality Assessment of Chromosomal Karyotype Analysis Based on Chimera Image Assembly.

Navigation between EQA and sustainability

Es geht voran! Aber Geschichte wird noch nicht gemacht

Benchmarking medical laboratory performance on a global scale

Benchmarking whole exome sequencing in the German network for personalized medicine

Longitudinal evaluation of external quality assessment results for CA 15-3, CA 19-9, and CA 125

External quality assurance in nongynecologic cytology: The Australasian experience

External Quality Assessment on Molecular Tumor Profiling with Circulating Tumor DNA-Based Methodologies Routinely Used in Clinical Pathology within the COIN Consortium

Navigating Quality Assessment Hurdles in Clinical Laboratory Services: A Comprehensive Review in Resource-Limited Settings

AWMF statement on medical services in laboratory diagnostics and pathology with regard to the IVDR